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Abstract
Background: Inflammatory reactions occurring in the brain after ischemia may contribute to
secondary damage. In the present study, effects of minocycline, an anti-inflammatory agent, alone
or in combination with mild hypothermia on focal embolic cerebral ischemia have been examined.
Methods: Focal ischemic injury was induced by embolizing a preformed clot into the middle
cerebral artery (MCA). Infarction volume was measured at 48 h after the injury. Mortality was also
recorded.
Results: Delayed administration of minocycline alone or delayed minocycline plus delayed mild
hypothermia reduced the infarction volume significantly. However, delayed mild hypothermia alone
was not protective and delayed mild hypothermia in combination with minocycline did not show
any additive effect.
Conclusions: These results suggest that minocycline is beneficial in focal ischemic brain injury, and
the lack of the enhanced neuroprotection may be due to the brief exposure to hypothermia.
Background
Inflammatory reactions occur within the brain after
ischemic injury and these may contribute to secondary
cerebral damage. Because inflammation reactions occur
rapidly and persist for at least a few days after ischemic
brain injury [2,7,11], these secondary responses are po-
tential targets for human therapy with a sufficiently wide
therapeutic window. Minocycline is a semisynthetic sec-
ond-generation drug of tetracycline group and it exerts
anti-inflammatory effects that are completely separate
and distinct from its antimicrobial action [12]. Minocy-
cline is used clinically for treatment of severe inflammato-
ry diseases and rheumatoid arthritis [12]. Recent studies
have shown that minocycline reduces the loss of hippoc-
ampal pyramidal neurons when used in a gerbil model of
global ischemia [20]. In a rat model of ischemia induced
by occlusion of the middle cerebral artery (MCA) with a
suture, minocycline is also an effective neuroprotective
agent [21]. Mild hypothermia induced before and after
ischemic brain injury reduces the structural, metabolic
and behavioral changes due to ischemia [4,14,15]. In glo-
bal ischemic injury model of repetitive forebrain
ischemia, we have demonstrated that mild hypothermia
protects neurons from damage [14]. We and other group
have also shown that the protective effect of mild hypo-
thermia can be enhanced by combination with other neu-
roprotective agents in global ischemic injury model
[3,5,15]. Mild hypothermia in combination with anti-in-
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flammatory treatment provides long-lasting neuroprotec-
tion of CA1 hippocampus following transient global
ischemia [3,5]. Combination of mild hypothermia and
drug therapy is also effective treatment for transient focal
cerebral ischemia [13]. However, effects of minocycline
and hypothermia on the embolic model of stroke have
not been examined. In the present study, we studied
whether: 1) minocycline is neuroprotective in a focal em-
bolic model of cerebral ischemia; 2) mild hypothermia af-
ter ischemic injury is neuroprotective in a focal embolic
model of cerebral ischemia; 3) combination of minocy-
cline and mild hypothermia is superior to either minoc-
yline or hypothermia alone.
Methods
Male Wistar rats, weighing 300–350 g, were used. Embolic
focal cerebral ischemia was induced by embolizing pre-
formed clot into the MCA [17,18]. The rectal temperature
of each rat was kept at 37°C throughout the surgery proce-
dure with a feedback controlled heating system. In hypo-
thermia groups, temperature was instituted by spraying
100% alcohol on the body of the rat while a fan circulated
room air around the animal, detailed previously [14,15].
The rectal temperature was kept at 34–35°C during the hy-
pothermia period. A mild degree of hypothermia was cho-
sen since it protects neurons from damage in both focal
and global ischemic injury [3,5,9,10,14]. We also found
that the mild hypothermia possessed an additive effect to
the protective actions of anti-glutamate agent in a global
ischemic injury model [15]. Furthermore, study has
shown a high correlation between brain and rectal tem-
peratures in focal ischemic brain injury model, with brain
temperature being higher than rectal temperature by 0.2
to 0.7°C [9].
The procedures for assessment of infarct volume have
been reported previously [19]. In brief, at the end of each
experiment (48 h after embolization) the brain was re-
moved and sectioned coronally with 2.0 mm of thickness
per section. The sections were stained with 2,3,5-triphe-
nyltetrazolium chloride (TTC) solution and scanned with
a flatbed color scanner (Scanjet 4p, Hewlett-Packard). The
images were analyzed using Adobe Photoshop. The total
volume of infarction was determined by integration of the
areas from these sections. The infarction volume was ex-
pressed as a percentage of the total volume from the ipsi-
lateral hemisphere.
The study consisted of four groups. In the control group
(n = 10), saline was injected. In the second group (n = 9),
minocycline (Sigma) was administered 1 and 4 h after
embolization on the first day, 45 mg/kg body weight i.p.,
and 24 and 32 h on the second day, 22.5 mg/kg. In the
third group (n = 9), minocycline was administered in the
same fashion as in the second group, but hypothermia
was also instituted. In the fourth group (n = 9), animals
received hypothermia treatment alone. In the present
study, hypothermia was started at 1 h after embolization
and hypothermia lasted for a period of two hours. Mino-
cycline was dissolved in distilled water and injection vol-
ume was 2 ml/per rat. The dose of minocycline used in the
study was based on previous works that showed, it effec-
tively reduces inflammation and protects against focal cer-
ebral ischemia in the ischemic brain [20,21].
The differences of infarction volume were analyzed with
one way ANOVA followed by Tukey test. The rates of mor-
tality following different treatments were compared with
Chi-square test. Differences were considered significant
when p < 0.05.
Results
Embolizing a pre-formed thrombus resulted in an infarc-
tion in the territory irrigated by the MCA, mainly located
in the cerebral cortex and striatum. In the control group
that received the saline injection, the infarction was 32 ±
3.2% of the volume from the ipsilateral hemisphere
(mean ± SEM) at 48 h after embolization (Fig. 1). In the
second group, administration of minocycline alone re-
duced the infarction volume by 42%, which was signifi-
cantly smaller than in the control group (P < 0.05). In the
third group, administration of minocycline plus hypo-
thermia resulted in the infarction volume being reduced
by 44% which was also significantly smaller than in the
control group (P < 0.05). However, the infarction volume
was not significantly different between the groups that re-
ceived minocycline alone and minocycline plus hypother-
mia. Compared to the control group, infarction volume
was reduced by 14% in the ischemic animals that received
hypothermia alone. This was not a significant difference
from the control group.
The mortality rates (Table 1) were three out of ten rats
(30%, one died within 24 h and two within 36 h after em-
bolization) in the control group; one out of nine rats
(11%, within 36 h) in the second group (minocylcine
alone). There was no significant difference in mortality
rates between those two groups (Chi-square; P > 0.05). In
the third group (minocycline and hypothermia) and the
fourth group (hypothermia alone), all rats reached the
end of the experiments. However, when the data were an-
alyzed with Chi-square test, the difference in mortality be-
tween the control group and the third or fourth group was
not significant (P > 0.05).
Discussion
In the present study, results show that minocycline, inject-
ed after embolization, was neuroprotective since the data
showed that infarction volume was decreased significant-
ly following minocycline treatment. The infarction vol-BMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/2
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ume was also reduced significantly in animals that
received treatment of minocycline in combination with
hypothermia. The reduction in infarction volume was
however the same in these two groups, i.e. minocycline
alone and minocycline plus hypothermia. Mild hypother-
mia instituted 1 h after ischemia with a period of two
hours did not reduce infarction volume significantly. In-
terestingly, no rat died prematurely in the groups treated
with hypothermia alone or in combination with minocy-
cline.
The present study demonstrates that minocycline treat-
ment benefits focal ischemia in an embolic stroke model
in rats. There are several possible mechanisms for its ben-
eficial actions. First, minocycline may reduce the infarc-
tion by inhibiting inflammatory reactions. Minocycline
has been used as a anti-inflammatory agent in many dis-
eases and, recently, it has been shown that minocycline
prevents microglia activation in the injured brain
[12,16,20]. Minocycline also inhibits production of other
inflammation mediators, for example, prostaglandin
(PG) E2[21]. Second, minocycline may inhibit the activity
of matrix metalloproteinases (MMP) and, MMP have
been found to worsen ischemic damage by increasing per-
meability of the brain blood barrier [21]. Additionally,
the protective actions of minocycline may also arise
through other mechanisms such as, inhibition of caspase,
inducible nitric oxide synthase (iNOS) and p38 mitogen-
activated protein kinase (MAPK) [6,8,16].
Studies have shown that mild or moderate hypothermia is
protective in models of transient or permanent MCA oc-
clusion [1,9,10]. Further, mild hypothermia in combina-
tion with drug therapy is more effective treatment than
hypothermia alone in transient cerebral ischemia [5,13].
Previously, our studies showed that mild hypothermia is
neuroprotective in global model of ischemic brain injury
when hypothermia was introduced during the induction
of ischemia [14]. In the present study, mild hypothermia
was instituted 1 h after ischemic injury, since this will be
more clinically relevant. Data showed that mild hypother-
mia started 1 h after ischemia, with a duration of two
hours, did not significantly reduce infarction size. Hypo-
thermia, in combination with minocycline, reduced inf-
arction volume but it did not further improve stroke
outcome than using minocyline alone. Since this is the
first study in which the neuroprotecive effects of hypo-
thermia were studied in a focal embolic stroke model, the
reason why delayed mild hypothermia is not neuropro-
tective is not clear. One reason can be that hypothermia
may protect ischemic brain injury more effectively in one
model than another, since the pathophysiology in differ-
ent models is not identical. For example, in the model
used in the present study fragments of the clots injected
moved downstream and occluded the downstream micro-
circulation after the clots in the larger arteries, the MCA
and ICA, are dissolved [18]. This is in contrast to the focal
ischemic injury model induced by insertion of a suture
into the ICA in which there will be no downstream move-
ment of clots. Secondly, the lack of neuroprotection of
mild hypothermia in the present study may also be due to
the delay in start of the treatment. These data may also im-
ply that prolonged hypothermia may be required to
achieve neuroprotective effects in this model. Despite the
fact that there was no reduction in infarction volume, hy-
pothermia, either alone or in combination with minocy-
Figure 1
Effects of minocycline alone or in combination with hypo-
thermia on percentage of the total volume from the ipsilat-
eral hemisphere following embolizing a pre-formed clot into
the MCA. Infarction volume was measured at 48 h after
embolization in TTC stained brain sections. Number of rats
in each group is indicated in the parenthesis above each bar.
Bar represents mean ± SEM and * denotes significant differ-
ence from the saline group (p < 0.05). The differences of inf-
arction volume were analyzed with one way ANOVA
followed by Tukey test. Mino: minocycline; hypo: hypother-
mia.
Table 1: Mortality in different groupsa
Group Saline (n = 10) Mino (n = 9) Mino+hypo 
(n = 9)
Hypo (n = 9)
24 h 1 0 0 0
36 h 2 1 0 0
Total 3 (20%) 1 (11%) 0 (0%) 0 (0%)
aMortality was recorded at 24 and 36 h after embolization. No death 
occurred later than 36 h after embolization. Mino.: minocycline; Hypo: 
hypothermiaBMC Neurology 2002, 2 http://www.biomedcentral.com/1471-2377/2/2
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cline, tended to reduce mortality in the ischemic animals.
No death occurred prematurely in the rats that received
treatment of either hypothermia alone or in combination
with minocycline, although statistical analysis did not
show significant difference when compared to the control
group. The lack of significant difference is probably due to
small sample size in this study.
Conclusions
The present study has demonstrated that treatment with
minocycline alone or in combination with hypothermia
reduces infarction volume in focal embolic brain injury.
Minocycline has been used clinically for treatment of pa-
tients with inflammatory diseases and rheumatoid arthri-
tis [12]. It has minimal side effects and is well tolerated in
the patients. Minocycline, therefore, could potentially be
a useful drug for treatment of stroke patients.
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